Ascletis Pharma Inc. (1672) Announces Completion of Enrollment in U.S. Phase IIa Study for Once-Monthly Subcutaneous Depot Formulation ASC30

Bulletin Express

Oct 20

Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 for obesity. According to official data, all 65 participants are obese or overweight with at least one weight-related comorbidity, and the 12-week randomized, double-blind, placebo-controlled, multi-center study is assessing safety, tolerability, and efficacy. Topline data are expected in the first quarter of 2026.

Previous research indicated a 46-day observed half-life of ASC30 in participants with obesity during a Phase Ib study, which supports once-monthly administration. The company revealed that ASC30’s ultra-long-acting subcutaneous depot treatment formulation demonstrated a terminal half-life of 36 days and a peak-to-trough ratio of approximately 1.5 to 1.

Ascletis Pharma Inc. stated that a conference call in Mandarin is scheduled on October 20, 2025, at 10:00 a.m. China Standard Time to further discuss this development. The investigational ASC30 GLP-1 receptor agonist, designed for both oral tablet and subcutaneous injection, remains protected by U.S. and global compound patents until 2044 without extensions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1122148696"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122148696\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122148696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 08:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122148696","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma Inc. (1672) Announces Completion of Enrollment in U.S. Phase IIa Study for Once-Monthly Subcutaneous Depot Formulation ASC30","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 for obesity. According to official data, all 65 participants are obese or overweight with at least one weight-related comorbidity, and the 12-week randomized, double-blind, placebo-controlled, multi-center study is assessing safety, tolerability, and efficacy. Topline data are expected in the first quarter of 2026.</p>\n<p>Previous research indicated a 46-day observed half-life of ASC30 in participants with obesity during a Phase Ib study, which supports once-monthly administration. The company revealed that ASC30’s ultra-long-acting subcutaneous depot treatment formulation demonstrated a terminal half-life of 36 days and a peak-to-trough ratio of approximately 1.5 to 1.</p>\n<p>Ascletis Pharma Inc. stated that a conference call in Mandarin is scheduled on October 20, 2025, at 10:00 a.m. China Standard Time to further discuss this development. The investigational ASC30 GLP-1 receptor agonist, designed for both oral tablet and subcutaneous injection, remains protected by U.S. and global compound patents until 2044 without extensions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Inc. (1672) Announces Completion of Enrollment in U.S. Phase IIa Study for Once-Monthly Subcutaneous Depot Formulation ASC30</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Inc. (1672) Announces Completion of Enrollment in U.S. Phase IIa Study for Once-Monthly Subcutaneous Depot Formulation ASC30\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-20 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 for obesity. According to official data, all 65 participants are obese or overweight with at least one weight-related comorbidity, and the 12-week randomized, double-blind, placebo-controlled, multi-center study is assessing safety, tolerability, and efficacy. Topline data are expected in the first quarter of 2026.</p>\n<p>Previous research indicated a 46-day observed half-life of ASC30 in participants with obesity during a Phase Ib study, which supports once-monthly administration. The company revealed that ASC30’s ultra-long-acting subcutaneous depot treatment formulation demonstrated a terminal half-life of 36 days and a peak-to-trough ratio of approximately 1.5 to 1.</p>\n<p>Ascletis Pharma Inc. stated that a conference call in Mandarin is scheduled on October 20, 2025, at 10:00 a.m. China Standard Time to further discuss this development. The investigational ASC30 GLP-1 receptor agonist, designed for both oral tablet and subcutaneous injection, remains protected by U.S. and global compound patents until 2044 without extensions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1122148696","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122148696","pubTimestamp":1760920148,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药(1672)宣布完成每月一次皮下储库制剂ASC30的美国IIa期研究入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 for obesity. According to official data, all 65 participants are obese or overweight with at least one weight-related comorbidity, and the 12-week randomized, double-blind, placebo-controlled, multi-center study is assessing safety, tolerability, and efficacy. Topline data are expected in the first quarter of 2026.\nPrevious research indicated a 46-day observed half-life of ASC30 in participants with obesity during a Phase Ib study, which supports once-monthly administration. The company revealed that ASC30’s ultra-long-acting subcutaneous depot treatment formulation demonstrated a terminal half-life of 36 days and a peak-to-trough ratio of approximately 1.5 to 1.\nAscletis Pharma Inc. stated that a conference call in Mandarin is scheduled on October 20, 2025, at 10:00 a.m. China Standard Time to further discuss this development. The investigational ASC30 GLP-1 receptor agonist, designed for both oral tablet and subcutaneous injection, remains protected by U.S. and global compound patents until 2044 without extensions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}